Signature Libraries

Product Name Product Description Specification
SL#001 Mcl-1 Apoptosis
Release: 04/12/2016

Apoptosis is now considered an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents.

In library: Mcl-1 inhibitors
SL#002 Bcl-xL Apoptosis
Release: 04/12/2016

Apoptosis is now considered an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents.

In library: BH3 mimetic-1
SL#003 Wnt/β-catenin Pathway Inhibitors
Release: 04/16/2016

Wnt cascade is mis-regulated in many human malignancies including 90% of colon cancers; therefore, blocking of Wnt signaling is considered an attractive therapeutic approach for colorectal cancer treatment [1,2].

In library: WNT pathway inhibitors
SL#004 Oncology Phenotypic Screening
Release: 04/14/2016

Deregulation of the balance between cell proliferation and death can lead to the formation of tumor malignancies. Signaling transduction pathways can regulate this process via the interaction of multiple functional extracellular and intracellular proteins such as kinases (e.g.

In library: Phenotypic Oncology
SL#005 Ion Channels-1. Nav1.8
Release: 04/24/2016

The blockage of voltage-gated sodium channels may effectively control such pathological conditions as chronic pain, epilepsy, and different arrhythmias.

In library: Sodium Channel Modulators
SL#006 Glycomimetics (Piperidines)
Release: 04/24/2016

Carbohydrates are fundamental components of every cell surface, where they are involved in vital cellular recognition processes.

In library: Glycomimetics
SL#007 Glycomimetics (Pyrrolidine)
Release: 04/25/2016

Carbohydrates are fundamental components of every cell surface, where they are involved in vital cellular recognition processes.

In library: Glycomimetics
SL#008 Glycomimetic Macrocycles-1
Release: 04/26/2016

Carbohydrates are the most abundant natural products. They participate in metabolism and serve as structural building blocks. Carbohydrates are fundamental constituents of every cell surface, where they are involved in vital cellular recognition processes.

In library: MACRO Glycomimetics
SL#009 Cell Permeable Macrocycles
Release: 04/28/2016

Macrocyclic chemotypes are unique due to their size, complexity, and ability to interact with so called “difficult targets”. Additionally, cyclization makes a molecule more drug-like, improving membrane permeability and metabolic stability.

In library: ADME
SL#010 Purine-based Nucleosides
Release: 04/29/2016

The enzyme co-factor SAM/SAH is found in all branches of life, widely exploited by protein methyltransferases for the transfer of a methyl group to various molecules of biological significance. A number of these enzymes are drug targets in the field of epigenetics [1].     

In library: Purine Nucleosides
SL#011 MDM2/p53
Release: 05/05/2016

MDM2/p53 is a protein-protein interaction (PPI) which regulates a variety of cellular pathways involved in the onset and development of cancer. MDM2 is a negative regulator of tumor suppression protein p53 thus making MDM2 an attractive target for anticancer therapeutics.

In library: PPI inhibitors-1 (MDM2/p53)
SL#012 Wnt/β-catenin Pathway Activators
Release: 05/06/2016

Re-activation of the Wnt/β-catenin pathway is essential for the regeneration of many tissues such as liver, brain, muscle, skin, and bone. Many publications suggest that Wnt pathway agonists or activators are desirable candidates for regeneration-enhancing therapies [1].

In library: WNT pathway activators
SL#013 Gram negative Antibacterials
Release: 05/08/2016

Drug resistance has created a need for new antibiotic discovery, development, and approval. This is especially true of Gram-negative bacterial pathogens as the problem has escalated over the past few years [1].

In library: Phenotypic antibacterial
SL#014 Peptide GPCR. SST4R agonists
Release: 05/09/2016

Neuropeptide somatostatin (SST or SRIF) is involved in multiple physiological functions including endocrine andexocrine hormone release, inhibition of tumor growth, cognition, sleep, and motor activity via binding to a GPCR family of SST receptors (SSTR) [1].

In library: SST-4 agonist
SL#015 Ser-Thr Kinases
Release: 05/12/2016

Approximately 125 of 500 human protein kinases are serine/threonine kinases (STK).

In library: Ser/Thr kinase inhibitors
SL#016 Glycomimetic Macrocycles-2
Release: 05/29/2016

Carbohydrates are fundamental constituents of every cell surface, where they are involved in vital cellular recognition processes. Glycomimetics are designed to mimic the structure of natural carbohydrates and modulate their disease-related function.

In library: MACRO Glycomimetics
SL#017 Aza Glycomimetics
Release: 05/14/2016

Polyhydroxylated secondary and tertiary amines are found among several interesting natural products having a wide range of biological activities due to their glycomimtic properties [1].

In library: Glycomimetics
SL#018 Spiro Peptidomimetics
Release: 05/17/2016

A variety of non-peptide small molecules that can mimic the structure or biological function of peptides have found application in drug discovery.

In library: Peptidomimetic
SL#019 Soft Electrophiles-1 Covalent Inhibitors
Release: 05/21/2016

In screening library creation, reactive molecules have been disregarded due to selectivity and safety concerns. However, many successful drugs act as covalent inhibitors based on a specific reactive group or moiety [1].

In library: Soft Electrophiles
SL#020 Soft Electrophiles-2 Covalent Inhibitors
Release: 05/21/2016

In screening library creation, reactive molecules have been disregarded due to selectivity and safety concerns. However, many successful drugs act as covalent inhibitors based on a specific reactive group or moiety [1].

In library: Soft Electrophiles
SL#021 IDO1 Inhibitors
Release: 06/15/2016

Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic enzyme involved in oxidative catabolism of local tryptophan along the kynurenine pathway. Elevated IDO1 activity inhibits both innate and adaptive immune responses resulting in irresponsiveness to immunological challenges.

In library: IDO inhibitors
SL#022 Soft Electrophiles-3. Covalent Inhibitors
Release: 06/05/2016

In screening library creation, reactive molecules have been disregarded due to selectivity and safety concerns. However, many successful drugs act as covalent inhibitors due to the presence of a specific reactive group or moiety [1].

In library: Soft Electrophiles
SL#023 Oncology Phenotypic Screening. Colon Cancer
Release: 07/28/2016

Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents for oncology drug discovery [1]. More specifically, in colon cancers multiple etiological pathways are responsible for disease onset and development [2].

In library: Phenotypic Oncology
SL#024 STAT-3 inhibitors
Release: 06/21/2016

STAT3 signaling is frequently activated in malignant cells leading to over-expression and accumulation of anti-apoptotic proteins. [1]. STAT3 is the lowest point of fusion of many signaling pathways, thus providing an attractive target for therapeutic intervention in the treatment of cancer [2].

In library: STAT3 pathway inhibitors
SL#025 BH3 mimetics
Release: 06/22/2016

Apoptosis is an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents [1].

In library: BH3 mimetic-2
SL#026 IRAK4 inhibitors
Release: 08/09/2016

Ser/Thr kinase IRAK4 is a key factor in the transduction of signals from the interleukin receptor (IL-1) and toll-like receptors (TLRs) resulting in cytokine release and promotion of genes controlled by transcription factor NF-kB in response to infection [1].

In library: IRAK4 inhibitors
SL#027 Soft Electrophiles-4. Covalent Inhibitors
Release: 06/25/2016

Historically, in screening libraries, reactive molecules have been disregarded due to selectivity and safety concerns. However, many successful drugs act as covalent inhibitors based on a specific reactive group or moiety [1].

In library: Soft Electrophiles
SL#028 Glycomimetics (Pyrrolidine)
Release: 04/06/2016

Carbohydrates are fundamental components of every cell surface where they are involved in vital cellular recognition processes. Despite their physiological importance they are rarely used as drugs due to their poor pharmacodynamic and pharmacokinetic properties.

In library: Glycomimetics
SL#029 IDH inhibitors
Release: 08/09/2016

Isocitrate dehydrogenase IDH 1 and 2 catalyze the conversion of isocitrate to αKG and play an important role in cancer metabolism. Mutations in IDH1/2 are reportedly responsible for oncogenesis of glioma, acute myeloid leukemia, and lymphoma.

In library: IDH inhibitors
SL#030 a-Helix mimetics
Release: 07/28/2016

α-Helix is the most common type of secondary structure in proteins [1]. It is well known that α-helix mimetics are biologically active in a number of therapeutically significant protein-protein interactions (PPIs). Notable examples include HDM2(HDM4)/p53 and the BCL-2 family of proteins.

In library: BH3 mimetic-1
SL#031 EZH2 inhibitors
Release: 09/07/2016

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme participating in DNA methylation (i.e. the addition of methyl group to histone H3 at lysine 27 which ultimately leads to the inhibition of transcription [1, 2] ).

In library: Epigenetics
SL#032 BH3 mimetics macrocycles
Release: 07/07/2016

Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; they can, therefore, be used as anticancer agents [1].

In library: BH3 mimetic macrocycles
SL#033: PD1/PD-L1 inhibitors
Release: 09/07/2016

Research has shown that Programmed Death-Ligand 1 (PD-L1) plays a role in suppressing the immune system in some physiological and pathological conditions.

In library: Immunology-Oncology
SL#034 beta-Turn Mimetic Macrocycles
Release: 07/09/2016

The mimicry of secondary structural elements of proteins with small molecules has proven to be a fruitful strategy in the design of protein-protein interaction (PPI) modulators [1].

In library: beta-Turn Mimetics
SL#035 MTT Macrocycles
Release: 07/11/2016

Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents in oncology drug discovery [1]. For example, in colon cancer multiple etiological pathways are responsible for disease onset and development [2]. 

In library: Phenotypic Oncology
SL#036 Glycomimetic Macrocycles-3
Release: 07/27/2016

Glyco-macrocycles are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Glyco-macrocycles are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.

In library: MACRO Glycomimetics
SL#037 Soft Electrophiles CN
Release: 08/19/2016

Covalent inhibitors often possess an electrophilic “warhead” which interacts with a nucleophilic residue at the binding site under certain physiological conditions; examples of such electrophilic groups include acrylamides, epoxides, nitriles, and electron-deficient ketones.  

In library: Soft Electrophiles
SL#038 Immuno Glycomimetics
Release: 07/18/2016

Oligosaccharides are key components in the antigen-antibody and host-pathogen recognition process. Despite the physiological importance of carbohydrates they are rarely used as drugs because of their poor pharmacodynamic and pharmacokinetic properties.

In library: Glycomimetics
SL#039 Glycomacrocycles-4
Release: 07/21/2016

Glycomacrocycles are an extremely interesting class of glycomimetics that occupy space between small and macro molecules. Glycomacrocycles are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.

In library: MACRO Glycomimetics
SL#040 Constrained tetrapeptides
Release: 07/25/2016

Therapeutic application of peptides has recently expanded to HIV, osteoporosis, cancer, and CNS-related disease.

In library: Peptidomimetic
SL#041 Voltage-gated sodium channels
Release: 08/02/2016
In library: Sodium Channel Modulators
SL#042 PKMT inhibitors
Release: 08/05/2016
In library: Methyltransferase inhibitors
SL#043 State1(T) inhibitors of activated Ras
Release: 08/08/2016
In library: GTPase inhibitors
SL#044 CNS set
Release: 08/11/2016
In library: ADME
SL#045 HDAC inhibitors
Release: 08/14/2016
In library: HDAC inhibitors
SL#046 xGFR inhibitors
Release: 08/17/2016
In library: Growth factor receptors inhibitors
SL#047 BET inhibitors
Release: 08/20/2016
In library: Bromodomain inhibitors
SL#048 ApoE activators
Release: 08/22/2016
In library: High-content screening
SL#049 SMO inhibitors
Release: 08/25/2016
In library: High-content screening
SL#050 Protease inhibitors
Release: 08/29/2016
In library: Protease inhibitors